IMAC Holdings, Inc., through its subsidiary, Ignite Proteomics LLC, provides proteomic product and precision medicine services based on activated protein analysis for the treatment of cancer in the United States. The company offers a reverse phase protein array (RPPA) platform, which can quantify protein signaling to support oncology clinical treatment decisions and biopharmaceutical drug development. IMAC Holdings, Inc. was founded in 2000 and is based in Franklin, Tennessee.